Difference between revisions of "Team:UiOslo Norway/Proof"

 
Line 1: Line 1:
 
{{UiOslo_Norway}}
 
{{UiOslo_Norway}}
 
<html>
 
<html>
 
+
 
 
   <div class="row subsite">
 
   <div class="row subsite">
 
<div class="col-md-12">
 
<div class="col-md-12">
Line 7: Line 7:
 
    
 
    
 
     <div class="col-md-6">
 
     <div class="col-md-6">
       <div id="proofofConcept"><h2 class="boxheader right"></h2></div>
+
       <div id=""><h2 class="boxheader right"></h2></div>
 
       <img class="sidephotocolor" src="https://static.igem.org/mediawiki/2016/a/a8/T--UiOslo_Norway--3dev.jpg"/>
 
       <img class="sidephotocolor" src="https://static.igem.org/mediawiki/2016/a/a8/T--UiOslo_Norway--3dev.jpg"/>
 
</div>
 
</div>

Latest revision as of 00:37, 20 October 2016

Proof Of Concept

As a proof of concept, we have successfully demonstrated all the central aspects of our projects with functioning set-ups.

Lab:
- Our colorimetric assay with nitrocefin is tested and validated, and our detection limits are within a clinically relevant range

- Using BBa_K1189031, a beta lactamase encoding biobrick designed by the Calgary team of 2013, we successfully showed that by using different combinations of inhibitors, we can pin-point the enzymatic class of the beta lactamase present in the samples.

- By purifying the BBa_K1189031 protein, testing it with nitrocefin and inhibitors and creating and validating our own biobricks for class A, B and C beta lactamases, we have demonstrated safe positive controls to test for these three classes of ESBLs.

Hardware:
Our 3D-printed case successfully interfaces urine samples to the phone, illuminates the sample,places and holds the samples on a optimal distance for camera focus.

Software:

We have successfully created an app with an user interface that accesses the camera, reads and analyze the color change induced by the cleavage of nitrocefin from a picture taken in our software. The app also includes an information page where users can read about guidelines regarding UTIs.

Thus, we present a functioning chassis for a mobile diagnostic platform that easily, and within minutes can identify the presence of ESBL producing bacteria in urine samples, without ever having to expose any bacteria to antibiotics.